Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > The list

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 16, 2022 10:31am

107 Views

Post# 34828933

RE:RE:RE:RE:RE:RE:RE:RE:The list

If you have a cancer type with +80% of patients expressing SORT you shouldn't need to pre-screen. If the drug is going to be useful the responders should flow. The claim is SORT is ubiquitous in some cancers. If it wasn't like this, if SORT was rare, then they should screen.

The most important difference in my view between 1a and 1b is that efficacy is front and centre. They have multiple cancers and they are looking for those that are viable for the drug. 1b is basically about finding a go/no go signal for each cancer. Can't remember if they said this or I just made this up but my idea is 2 out of 10 patients in one cancer would allow that cancer to potentially move forward to the next phase.